

Curriculum Vitae

Kobold Sebastian Professor, Dr. med.
d.o.b. August 26th, 1983, in Würzburg, Germany

University Education

2010 **Doctorate in medicine** with *magna cum laude*
2007 **State medical boards** and successful completion of medical studies
2004 - 2007 **Doctoral thesis** in the laboratory of Prof. Dr. Renner and Prof. Dr. Knuth in Homburg and Zürich
2001 - 2007 **Medical studies** at the Faculty of Medicine Saarland University, Homburg, Germany

Scientific Career

2025 - present **Director**, Institute of Clinical Pharmacology, LMU Klinikum
Professor and Chair of Clinical Pharmacology, Ludwig-Maximilians-Universität München, Germany
2024 - present **Speaker** of the Marie-Sklodowska-Curie Innovative Training Network T-RAFIC
2022 - present **Speaker**, BAYCELLator “Bavarian Cell Therapy Catalysator” funded by the Bayerische Transformations- und Forschungsstiftung
2021 - present **Speaker** of the Clinician-Scientist Program “Immunoncology and Local Interventions, IOLIN”, funded by the Else-Kröner-Fresenius-Stiftung
2020 - 2025 **Speaker** of the Marie-Sklodowska-Curie Innovative Training Network T-OP
2019 - 2025 **Professor for experimental immunoncology and deputy Director**, Ludwig-Maximilians-Universität München, Munich, Germany
2018 **Visiting Professor**, Luigi-Vanvitelli-University of Naples, Italy
2016 - 2025 **Attending Physician** (Oberarzt), Division of Clinical Pharmacology, Department of Internal medicine IV, Director: Prof. Dr. Endres
2015 - 2019 **Scientific coordinator and applicant** of the Marie-Sklodowska-Curie Innovative Training Network “IMMUTRAIN” (Speaker: S. Endres)
2014 **Board certification in clinical pharmacology** by the Bavarian Chamber of physicians
Board certification in immunology by the German Society of Immunology
Habilitation in experimental internal medicine, Medical Faculty of the Ludwig-Maximilians-Universität München
2014 - present **Scientific coordinator and applicant** of the international training network “i-Target: immunotargeting of cancer”, supported by the Elite Network of Bavaria (Speaker: S. Endres)
2013 **Visiting Researcher**, Laboratory of Prof. Kai Wucherpennig, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
2011 - present **Group leader**, immunopharmacology group. Division of Clinical Pharmacology, Department of Internal medicine IV, Director: Prof. Dr. Endres
2009 - 2016 **Post-Doc and Resident** in the Division of Clinical Pharmacology, Department of Internal medicine IV, Director: Prof. Dr. Endres
2008 - 2009 **Post-Doc and Resident** at the Clinic for oncology, hematology and stem cell transplantation with the section Pneumology, University Medical Center Hamburg-Eppendorf, Director: Prof. Dr. Bokemeyer

Awards and Honors (selection)

2024 Wilhelm-Vaillant-Award for Medical Research 2024
Rolf Becker Award for Medical Research 2024
European Research Council (ERC) Consolidator Grant
2023 Georges-Köhler-Award of the German Society for Immunology

- 2022 Cancer Research Award of the Berlin-Brandenburg Academy of Science, sponsored by the Monika-Kutzner Foundation
- 2021 Lisec-Artz-Award for Cancer Research, University of Bonn, Germany
- 2019 M4-Award for biomedical entrepreneurship, awarded by the Bavarian Ministry of Economic Affairs
Johann-Georg-Zimmermann Preis für Krebsforschung, awarded by Medizinische Hochschule Hannover
- 2017 European Research Council (ERC) Starting Grant
- 2016 Vincenz-Czerny Award for cancer research, awarded by the German Society of Hematology and Oncology
Ernst-Jung Karriereförderpreis 2016, awarded by the Ernst-Jung-Stiftung

Citation Record

Total citations: 11.559; *h-index*: 55; *h-index since 2021*: 45 (Google Scholar January 21th, 2026)

Top-10 selected Publications

- Gottschlich A, Grünmeier R, Hoffmann GV, Nandi S, Kavaka V, Müller PJ, Jobst J, Oner A, Kaiser R, Gärtig J, Piseddu I, Frenz-Wiessner S, Fairley SD, Schulz H, Igl V, Janert TA, Di Fina L, Mulkers M, Thomas M, Briukhovetska D, Simnica D, Carlini E, Tsiverioti CA, Trefny MP, Lorenzini T, Märkl F, Mesquita P, Brabenec R, Strzalkowski T, Stock S, Michaelides S, Hellmuth J, Thelen M, Reinke S, Klapper W, Gelebart PF, Nicolai L, Marr C, Beltrán E, Megens RTA, Klein C, Baran-Marszak F, Rosenwald A, von Bergwelt-Baildon M, Bröckelmann PJ, Endres S, **Kobold S**. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. **Blood**. 2025 Apr 3;145(14):1536-1552. doi: [10.1182/blood.2023022197](https://doi.org/10.1182/blood.2023022197). PMID: 40178843
- Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, **Kobold S***, Böttcher JP*. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. **Nature**, 2024; May;629(8011):417-425. * share senior authorship. doi: [10.1038/s41586-024-07254-x](https://doi.org/10.1038/s41586-024-07254-x). PMID: 38658748
- Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, **Kobold S***, Binder M*. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. **Nature Communications**, 2024; Feb 2;15(1):993. * share senior authorship. doi: [10.1038/s41467-024-45378-w](https://doi.org/10.1038/s41467-024-45378-w). PMID: 38307904.
- Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmner P, Grünmeier R, Carlini E, Tsiverioti CA, **Kobold S***, Funke JJ*, Dietz H*. Programmable multispecific DNA-origami-based T-cell engagers. **Nat Nanotechnology**, 2023; Nov;18(11):1319-1326. doi: [0.1038/s41565-023-01471-7](https://doi.org/10.1038/s41565-023-01471-7). * share senior authorship. PMID: 37591933
- Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller PJ, Dörr J, Seifert M, Cadilha BL, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, **Kobold S**. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. **Nat Biotechnology**, 2023; Nov;41(11):1618-1632. doi: [10.1038/s41587-023-01684-0](https://doi.org/10.1038/s41587-023-01684-0). PMID: 36914885
- Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, **Kobold S**. T cell-derived interleukin-22 drives the expression of CD155 by cancer

- cells to suppress NK cell function and promote metastasis. **Immunity**, 2023; Jan 10;56(1):143-161.e11. doi: [10.1016/j.immuni.2022.12.010](https://doi.org/10.1016/j.immuni.2022.12.010). PMID: 36630913
7. Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, and **Kobold S**. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors. **Journal for the Immunotherapy of Cancer**, 2022;10(7):e005054. doi: [10.1136/jitc-2022-005054](https://doi.org/10.1136/jitc-2022-005054). PMID: 35902133
 8. Briukhovetska D, Dörr J, Endres S, Libby P, Dinarello CA, **Kobold S**. Interleukins in cancer: from biology to therapy. **Nature Reviews Cancer**. 2021 Aug;21(8):481-499. doi: [10.1038/s41568-021-00363-z](https://doi.org/10.1038/s41568-021-00363-z). PMID: 34083781
 9. Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadiou E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, **Kobold S**. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. **Nature Biomedical Engineering**, 2021; Nov;5(11):1246-1260. doi: [10.1038/s41551-021-00737-6](https://doi.org/10.1038/s41551-021-00737-6). PMID: 34083764
 10. Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vääntinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S and **Kobold S**. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cells to reject solid tumors. **Science Advances**, 2021; 7(24):eabi5781. doi: [10.1126/sciadv.abi5781](https://doi.org/10.1126/sciadv.abi5781). PMID: 34108220